| 2010-12-06: |
Follow - Up Results from Study Comparing SPRYCEL( R ) ( dasatinib ) to Imatinib in First - Line Treatment of Adults with Ph+ CP - CML Demonstrate Improved Response Rates Consistent with 12 Month Data[1]
Princeton, New Jersey and Tokyo ( PRN/ots ) - Bristol - Myers Squibb Company ( http://www.bms.com ) and Otsuka Pharmaceutical Co., Ltd. today announced 18 - month follow - up results from the Phase 3 DASISION study of SPRYCEL( R ) ( dasatinib ) 100 mg once daily vs. imatinib ( 400 mg daily ) (...) |
| 2005-09-01: |
P&G Finalises Acquisition of Sanofi - Aventis' Oral Care Brands
Geneva, Switzerland ( PRN/ots ) - - Pharmacy Channel Capability - Important Step to Oral Care Leadership The Procter & Gamble Company ( NYSE: PG ) today announced that it has finalised the acquisition of Sanofi - aventis' global portfolio of trusted oral care brands for an undisclosed sum. (...) |
| 2008-11-05: |
Personalising Cancer Care - An Invitation
Ingelheim, Germany, November 5 ( PRN/ots ) - - For Non - US Healthcare Media Can the quest for personalised medicine in cancer therapy ever be realised? And how far have we come in the journey to personalised cancer care? What lies ahead from (...) |
| 2005-10-31: |
Sanofi Pasteur Announces Agreement to License Novel Adjuvant From Eisai Co., Ltd
Lyon, France and Swiftwater, Pennsylvania ( PRN/ots ) - Sanofi pasteur, the vaccines business of the sanofi - aventis Group ( NYSE: SNY ), has entered into an agreement with Eisai Co., Ltd. to license their novel adjuvant, E6020, for use in the development of new vaccines to (...) |
| 2011-03-23: |
Prolia( R ) ( denosumab ) Open - Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
Thousand Oaks, California ( PRN/ots ) - Amgen today announced new long - term data showing that during the fourth and fifth years of Prolia( R ) ( denosumab ) treatment, postmenopausal women with osteoporosis receiving Prolia continued with further, statistically significant, year - over - year increases in lumbar spine and total hip (...) |
| 2011-03-21: |
First Social Network for Osteoporosis Launches at Global Patient Conference
Valencia, Spain ( PRN/ots ) - On Friday 18 March the International Osteoporosis Foundation ( IOF ) announced the launch of OsteoLink, a new social network for people affected by osteoporosis. Through OsteoLink, the IOF will create the first global online and in - person network dedicated to improving (...) |
| 2008-10-22: |
Boehringer Ingelheim Broadens Oncology Pipeline With Promising New Data for Potentially First in Class Plk1 Inhibitor
Ingelheim, Germany ( PRN/ots ) - - BI 6727, a Highly Potent and Selective Plk1 inhibitor, Represents Latest Advance in Company's Plk1 Programme - For non - US Healthcare Media Boehringer Ingelheim's most promising new cell cycle kinase inhibitor and potentially first - in - class compound, BI (...) |
| 2009-03-23: |
With New National Immunisation Programme in Saudi Arabia, Thirty - Five Countries Now Offer Routine Immunisation Against Pneumococcal Disease With Prevenar
Maidenhead, England ( PRN/ots ) - - Prevenar Helps Protect Children Against the Leading Vaccine - Preventable Cause of Death in Children Younger than Five Years of Age Worldwide Wyeth today announced that Prevenar( TM ) ( Pneumococcal saccharide conjugated vaccine, Adsorbed ) has been added to Saudi Arabia's national childhood (...) |
| 2011-02-10: |
Zebinix, Novel Once - Daily Anti - Epileptic Treatment, Launches in Spain
Hatfield, England ( PRN/ots ) - Zebinix( R ) ( eslicarbazepine acetate ), an add - on ( adjunctive ) therapy for adults with partial - onset seizures, with or without secondary generalisation ( where the seizure spreads to both sides of the brain ), has been launched today in Spain by Eisai and BIAL in (...) |
| 2007-12-13: |
New Online Learning Tool Fills the Knowledge Gap on Botulinum Toxin Type B for Cervical Dystonia
Malvern, Pennsylvania ( PRN/ots ) - - Solstice Neurosciences, Inc. Launches a Self - Guided Lesson as Prep for In - Person Workshops In recognition that physician comfort and knowledge with techniques around botulinum toxin injections lead to the best results for patients with cervical dystonia ( CD ), (...) |
| 2011-03-30: |
Amgen to Appeal CHMP Opinion on Vectibix( R ) ( Panitumumab ) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe
Thousand Oaks, California ( PRN/ots ) - Amgen announced today that it has submitted a request to the European Medicines Agency ( EMA ) for a re - examination of the negative opinion issued in March by the Committee For Medicinal Products for Human Use ( CHMP ) for the use (...) |
| 2005-09-12: |
Bayer and Onyx Announce European Marketing Submission for Sorafenib
West Haven, Connecticut, and Emeryville, California ( PRN/ots ) - - European Trial to Provide Access to Sorafenib for Individuals with Advanced Renal Cell Carcinoma Bayer Pharmaceuticals Corporation ( NYSE: BAY ) and Onyx Pharmaceuticals, Inc. ( Nasdaq: ONXX ) today announced that a Marketing Authorization Application ( MAA ) has been (...) |
| 2009-05-20: |
BIO International Convention 2009: Research Location Germany Presents Potential in Regenerative Medicine
Atlanta ( na Originaltextservice ) - Germany will present itself as one of the world's leading regenerative medicine research locations at this year's BIO International Convention. Under the "Breakthroughs in Regenerative Medicines in Germany" banner, German experts will provide invaluable insight into the latest research (...) |
| 2010-12-20: |
Daiichi Sankyo Announces First European Approval for Sevikar HCT( R ), a New Three - in - one Combination Product for the Treatment of High Blood Pressure*
Munich ( PRN/ots ) - Daiichi Sankyo Europe announced today that Sevikar HCT( R ) is now approved in Germany, the first market to launch this new once - daily three - in - one combination product for the treatment of high blood pressure ( BP ). This new drug combines the three (...) |
| 2004-11-16: |
New ASCO Recommendation for Postmenopausal Women With Early Breast Cancer
London, November 15 ( PRN/ots ) - - Optimal Adjuvant Therapy Should Now Include an AI Such as 'Arimidex' ( anastrozole ) in Order to Reduce the Risk of Tumour Recurrence Today, the American Society of Clinical Oncology ( ASCO ) Technology Assessment Panel announced a fundamental change to (...) |
| 2007-12-19: |
Avastin Approved in Europe for First - Line Treatment of Patients With Advanced Kidney Cancer
Basel ( PRN/ots ) - - Avastin Offers Patients the Chance to Live Twice as Long Without Their Disease Advancing Avastin ( bevacizumab ), Roche's innovative anti - cancer drug, was approved today in Europe for the first - line treatment of patients with advanced renal cell cancer ( RCC ) (...) |
| 2007-06-26: |
SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Calgary, Canada ( PRN/ots ) - - Canadian Biotechnology Company Updates Progress and Upcoming Milestones on its Insulin Program - TSX symbol: SBS SemBioSys Genetics Inc. ( TSX:SBS ), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular disease, today announced positive preclinical (...) |
| 2010-01-21: |
New Real World Avastin Data From Over 3,200 Metastatic Colorectal Cancer Patients Confirms Survival Benefit Beyond 2 Years
Basel, Switzerland ( PRN/ots ) - New data from two large studies observing the routine use of Avastin - based therapy in more than 3,200 patients will be announced showing impressive treatment benefits in a non - selected patient population. Key findings included high rates of tumour shrinkage (...) |
| 2009-09-24: |
Vectibix( R ) in Combination With Chemotherapy Significantly Improves Progression - Free Survival in First - Line Metastatic Colorectal Cancer
Thousand Oaks, California ( PRN/ots ) - Amgen ( Nasdaq: AMGN ) today announced detailed results from the Phase 3 '203' trial evaluating Vectibix( R ) ( panitumumab ) administered in combination with FOLFOX ( an oxaliplatin - based chemotherapy ) as the first - line treatment of metastatic colorectal cancer ( mCRC ). In this trial, (...) |
| 2007-11-06: |
Shire Announces Results of FOSRENOL( R ) Study in Pre - Dialysis CKD Stage 3 & 4 Patients
Philadelphia and Basingstoke, England, November 6 ( PRN/ots ) - Shire plc ( LSE: SHP, NASDAQ: SHPGY, TSX: SHQ ) today announced the results of a Phase II study indicating that FOSRENOL can effectively reduce serum phosphate levels in chronic kidney disease ( CKD ) patients not on dialysis.( 1 ) (...) |
| 2010-10-22: |
Occlutech Wins Dutch Appeal Court Ruling Against AGA Medical
Jena, Germany ( PRN/ots ) - Occlutech GmbH, the leading European developer of minimally invasive implants for the treatment of structural heart disease, today announced receiving a favourable appeal court ruling from The Hague, The Netherlands in the on - going patent litigation with AGA Medical. A (...) |
| 2008-05-07: |
Women Suffering From Decreased Sexual Desire: Silence Hinders Diagnosis of the Prevalent Condition Hypoactive Sexual Desire Disorder ( HSDD )
Ingelheim, Germany ( PRN/ots ) - - For Non - US Media - Boehringer Ingelheim Announces Commitment to Progressing Science in This Area of Unmet Medical Need With the 'Bouquet' Studies. Data announced at this week's American College of Obstetricians and Gynecologists ( ACOG ) annual clinical meeting suggest (...) |
| 2010-03-19: |
Levact( R ) ( bendamustine ) Recommended for Approval in Europe for Treating Blood Cancers
Cambridge, England, March 19, 2010 ( PRN/ots ) - Mundipharma announced today that the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has issued a positive opinion recommending that marketing authorisations can be granted in Germany and the following Member (...) |
| 2010-05-26: |
First Major Survey of Multiple Sclerosis ( MS ) Nurses Highlights Significant Disparities in MS Nursing Across Europe
Brussels, May 26, 2010 ( PRN/ots ) - The first major survey of European Multiple Sclerosis ( MS ) nurses revealed that nearly one in three nurses ( 31 Prozent ) reported that standards of MS care are not adequately maintained in their country. The results of this survey will be (...) |
| 2007-05-01: |
President of CBM Prof. Allen Foster Says "The Olympics Will Offer Tremendous Help in Raising Awareness About Poverty"
Toronto ( PRN/ots ) - "The Beijing 2008 Summer Olympics promises to be an historic event for the world of sports and for people worldwide," says Secretary - General Ban Ki - moon's Special Adviser on Sport for Development and Peace. Adolf Ogi has scheduled a meeting (...) |
| 2011-04-19: |
Zebinix( R ) Now Available in Greece
Hatfield, England ( PRN/ots ) - Zebinix( R ) ( eslicarbazepine acetate ), an add - on ( adjunctive ) therapy for adults with partial - onset seizures, with or without secondary generalisation ( where the seizure extensively affects consciousness of the patients by propagation to both sides of the brain ), has recently been launched in (...) |
| 2007-02-26: |
U.S. Regulators Approve Cymbalta( R ) for Treatment of Generalised Anxiety Disorder
Indianapolis ( PRN/ots ) - The U.S. Food and Drug Administration ( FDA ) has approved the antidepressant Cymbalta( R ) ( duloxetine HCl ) for the treatment of generalised anxiety disorder ( GAD ), Eli Lilly and Company ( NYSE: LLY ) and Boehringer Ingelheim announced today. The approval is based on the (...) |
| 2007-03-29: |
Pieris demonstrates potent anti - tumor activity of a VEGF - specific Anticalin® in preclinical studies
Freising - Weihenstephan, Germany ( na Originaltextservice ) - Pieris demonstrates potent anti - tumor activity of a VEGF - specific Anticalin® in preclinical studies Pieris AG, a bio - pharmaceutical company developing therapeutic products comprising of Anticalins®, a novel proprietary class of human binding proteins, (...) |
| 2008-05-31: |
Catumaxomab, Representing a New Generation of Antibodies, Proved Efficient and Safe in Malignant Ascites / Data presented at 44th annual ASCO congress, Chicago, USA
München, Deutschland und Chicago, USA ( na Originaltextservice ) - Treatment with the trifunctional antibody catumaxomab significantly prolongs puncture - free survival in patients with malignant ascites, according to the results from a Phase II/III trial presented at the 44th American Society of Clinical (...) |
| 2006-03-20: |
Isotechnika Announces Preliminary 48 Week Clinical Data From the Phase III ISA247 Psoriasis Trial
Edmonton, Canada ( PRN/ots ) - Isotechnika Inc. ( TSX:ISA ) announced today preliminary 48 week clinical data obtained from its Phase III psoriasis and extension trials for its lead immunosuppressive drug, ISA247. Patients completing the 24 week Canadian Phase III SPIRIT trial were given the opportunity (...) |
| 2005-11-04: |
Media Advisory - Isotechnika to Announce Phase III Psoriasis Spirit Trial Results
Edmonton, Canada, November 4 ( PRN/ots ) - - ATTN: Business/Assignment Editors: EDMONTON, Canada, November 4 /PRNewswire/ - - Isotechnika Inc. will announce the unaudited 24 week data for the Company's Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247 on Monday, (...) |
| 2008-09-10: |
Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS( R ) and APIDRA( R ) Achieved Greater Reductions in A1C Than Those Treated With Pre - mixed Insulin
Paris ( PRN/ots ) - - Abstracts 186 and 1003 Sanofi - aventis announced today that results from two studies, GINGER and LACE, presented at the 44th annual meeting of the European Association for the Study of Diabetes ( EASD ) demonstrated that a basal - bolus insulin regimen (...) |
| 2009-05-30: |
Maintenance Treatment With Avastin and Tarceva in Combination Helps Lung Cancer Patients Live Longer Without Their Disease Worsening
Basel, Switzerland ( PRN/ots ) - - For ex - US Media Only - Phase III ATLAS Study Achieves a New Milestone in Treating Advanced Lung Cancer Roche announced today that the Phase III ATLAS study showed patients with advanced non - small cell lung cancer ( NSCLC ) (...) |
| 2008-09-22: |
Alzheimer's Disease International ( ADI )( 1 ) Launches Worldwide Campaign to Address Growing Public Health and Social Care Emergency
London ( PRN/ots ) - - Immediate Action Needed to Prepare for 100 Million Cases of Devastating Brain Disease Worldwide Expected by 2050( 2 ) A global call for action to address the growing public health and social care emergency posed by Alzheimer's disease and related dementias (...) |
| 2004-12-03: |
Moulin and Golden Gate Capital Acquire Eye Care Centers of America, the Second Largest Optical Retail Chain in the US
Hong Kong ( PRN/ots ) - - Integrates the Largest Frame Manufacturer in Asia with the Most Powerful Value Proposition in the US Retail Market Moulin International Holdings Limited ( "Moulin" / the "Group" )( stock code: 389 ), a global leader in the manufacturing, distribution and retailing of eyewear, (...) |
| 2010-07-22: |
Kowa Announces Successful EU Regulatory Application for Pitavastatin
Wokingham, England, July 22, 2010 ( PRN/ots ) - Kowa are delighted to announce that following the completion of the decentralized regulatory procedure, that their statin, pitavastatin has achieved a positive outcome from the UK Regulatory Authority ( MHRA ) acting as the Reference Member State for 16 (...) |
| 2010-11-20: |
Good News for Kidney Patients: World's Largest Kidney Disease Trial Shows Big Benefits From Reducing Cholesterol
Denver, November 20 ( PRN/ots ) - Around a quarter of all heart attacks, strokes, and operations to open blocked arteries could be avoided in people with chronic kidney disease by using the combination of ezetimibe and simvastatin to lower blood cholesterol levels. That's the conclusion (...) |
| 2007-09-19: |
New Research Shows ACTOS( R ) ( pioglitazone HCI ) is Associated With a 38 Prozent Lower Risk of Heart Attack in Type 2 Diabetes
Amsterdam ( PRN/ots ) - - For Non - US Media Only New research, including two studies presented this week at the 43rd Annual Meeting of the European Association for the Study of Diabetes ( EASD ), further support the cardiovascular safety of ACTOS( R ) ( pioglitazone HCI ) and its (...) |
| 2006-11-13: |
New Study Indicates Boosted Invirase 500 Patients Achieve Similar Levels of Viral Suppression to Boosted Lopinavir but with a Better Lipid Profile
Glasgow, Scotland, November 13 ( PRN/ots ) - - Patients Treated With Boosted Invirase 500 Were Significantly Less Likely to Develop Elevated Lipids Than Boosted Lopinavir Promising head to head results presented today indicate that the boosted protease inhibitor ( PI/r ) Invirase 500/r (...) |
| 2005-02-01: |
Medex Announces Tsunami Relief Efforts
Carlsbad, California ( PRN/ots ) - - Medex Commits More Than US$1.4 Million in Medical Product Contributions Medex, a global manufacturer and marketer of medical devices, announced today that it has authorized medical product donations of more than US$1.4 million to assist with relief efforts (...) |
| 2006-04-24: |
Pieris enters into a collaborative research and option agreement with GE Healthcare
Freising - Weihenstephan, Germany ( na Originaltextservice ) - Pieris Proteolab AG and GE Healthcare today announced that they have entered into a research collaboration for the discovery of novel targeted in vivo diagnostic and medical imaging compounds, a technology that could enable earlier detection and diagnosis of major (...) |
| 2007-07-20: |
Organon's Marketing Authorization Application for Sugammadex Accepted for Review by EMEA
Oss, The Netherlands ( PRN/ots ) - Organon, the human healthcare business unit of Akzo Nobel, announced today that the Marketing Authorization Application ( MAA ) for sugammadex has been accepted for review by the European Medicines Agency ( EMEA ). This novel selective relaxant binding agent ( SRBA ) is specifically designed (...) |
| 2007-03-06: |
Clinical Solutions Selected for First Portuguese Health Helpline
Basingstoke, England ( PRN/ots ) - Clinical Solutions, a leading British provider of software solutions to the healthcare market, has been selected to provide call centre management and clinical decision support software for the Portuguese Public Health System. The software will be used by staff manning (...) |
| 2010-06-07: |
Survey Reveals Many are Ignoring Basic Measures to Check for no.1 Heart Killer Disorder in Europe
STRATFORD - UPON - AVON, England, June 7, 2010 ( PRN/ots ) - Arrhythmia Alliance, the Heart Rhythm Charity, announced today the results of a survey conducted in Europe that showed a large number of respondents ignore basic measures to check for potential cardiac arrhythmias, or heart rhythm (...) |
| 2007-06-02: |
Avastin( R ) Significantly Prolongs Progression Free Survival in Patients With Advanced Lung Cancer
Chicago, Illinois ( PRN/ots ) - - Only First - line Treatment to Demonstrate Extended Survival in Over a Decade Avastin ( bevacizumab ), significantly improves the time patients with advanced non - small cell lung cancer ( NSCLC ) live without their disease advancing ( "progression free survival" ) when added to cisplatin/ (...) |
| 2006-06-13: |
More Than 80 Percent of People With Parkinson's Disease Experience Symptoms of Depression, but Nearly Half are not Discussing Them With Their Doctor
Amsterdam ( na Originaltextservice ) - - New Pan - European Sociological Survey Announced by the European Parkinson's Disease Association ( EPDA ), Reveals the 'Hidden Face' of PD Over 80 percent of surveyed people with Parkinson's disease ( PD ) 'often' or 'sometimes' suffer from depressive symptoms (...) |
| 2005-11-11: |
Invitation to the launch of the "Degussa European Science - to - Business Award"
Düsseldorf - Dear Sir/Madam, We cordially invite you to the launch of our "Degussa European Science - to - Business Award": Tuesday, November 22, 2005, 6:30 pm at the Bibliothèque Solvay Parc Leopold, Rue Belliard 137, Brussels By sponsoring this (...) |
| 2008-07-29: |
SemBioSys Submits IND for Safflower - Produced Insulin to U.S. FDA
Calgary ( PRN/ots ) - - Submission Demonstrates Progress of Plant - Derived Insulin Program Scheduled to Enter the Clinic Later This Year SemBioSys Genetics Inc. ( TSX:SBS ), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that it (...) |
| 2007-07-10: |
Pieris progresses proprietary asthma program: validation of pulmonary delivery of Anticalin® - based protein product candidate
Freising - Weihenstephan, Germany ( na Originaltextservice ) - Pieris AG, a bio - pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, today announced significant progress in validating novel, effective products for the potential treatment of asthma. In studies of its (...) |
|
|
back...
1
2
3
4
5
6
7
8
9
10
11
more... |
